Anson Group, a sponsor for Rare Disease Day, hopes to bring more attention to the need for finding more treatments for diseases which affect a smaller patient population.
Indianapolis, IN (Vocus) February 27, 2010 -- The Anson Group hopes to draw more attention to the urgent need of finding more treatments for rare diseases by partnering with the National Organization for Rare Diseases (NORD) to sponsor Rare Disease Day in the United States, February 28th, 2010.
Anson Group, a regulatory consulting company, has had the privilege of providing regulatory support for multiple products that are indicated for the treatment of a number of rare diseases. Anson has aided clients in obtaining Orphan Drug status (for pharmaceutical entities) and Humanitarian Use Designations (for medical devices) for products intended to treat diseases like gastrointestinal stromal tumor (GIST), mastocytosis and multiple myeloma, as well as multiple sclerosis and amyotrophic lateral sclerosis (ALS). Most recently, Anson Group helped prepare materials for an FDA Advisory Committee meeting regarding a new treatment for Niemann-Pick Type C (NPC) disease.
Anson supports the need for continued research and innovation in rare diseases. As scientists continue to work to evolve treatments to target more specific disease pathways, subpopulations and rare diseases will become increasingly important in the understanding and practice of true personalized medicine. Anson Group will continue to invest in building our expertise in regulatory requirements for these products in order to expand our role in ensuring promising treatments reach the market for those who suffer from rare conditions.
“Anson is proud of our 15 year history of helping all of our clients get their medical technologies to market as quickly as possible and in compliance with the applicable regulations; that said, no project
Copyright©2010 Vocus, Inc.
All rights reserved